InnoCare Pharma Announces Exclusive Commercialization Partnership with Huadong Medicine for PARP Inhibitor Senaparib in China

Today, Shanghai Junpaiyingshi Pharmaceutical Co., Ltd. (hereinafter referred to as “IMPACT Therapeutics”), a subsidiary of Nanjing Impact Therapeutics Inc. and an innovative drug R&D company focused on the mechanism of synthetic lethality in oncology, announced a collaboration with Hangzhou Huadong Medicine Co., Ltd. (hereinafter referred to as “Huadong Medicine”), a wholly-owned subsidiary of Huadong Medicine Co.,Ltd. (SZ.000963), regarding the commercial promotion of Senaparib (IMP4297), an innovative PARP inhibitor (hereinafter referred to as the “Licensed Product”), in mainland China. Huadong Medicine will obtain exclusive marketing rights for Senaparib in mainland China. Zhoudou Capital served as the exclusive financial advisor to IMPACT Therapeutics.

Dr. Cai Suixiong, CEO of IMPACT Therapeuticsstated, “We are delighted to enter into this collaboration with Huadong Medicine, which will undoubtedly maximize the market value of Senaparib in China. Following its approval and launch, Senaparib is poised to become a new PARP inhibitor indicated for first-line maintenance therapy across the entire population of patients with advanced ovarian cancer in China, demonstrating best-in-class potential. We firmly believe that Huadong Medicine’s robust commercialization capabilities and extensive promotional expertise will be deeply integrated with the substantial clinical value of Senaparib, thereby enabling it to benefit more oncology patients in the future.”

Lü Liang, Chairman and General Manager of Huadong Medicinestated: “IMPACT Therapeutics possesses robust experience in innovative drug R&D. The New Drug Application (NDA) for senaparib was accepted by the NMPA in August 2023. This product demonstrates strong synergy with Huadong Medicine’s existing ovarian cancer pipeline. We will collaborate with IMPACT Therapeutics to actively advance the commercialization of senaparib in China, thereby providing ovarian cancer patients with more numerous, more effective, and safer therapeutic options.”

Under the relevant agreement terms, Huadong Medicine will be responsible for the commercial marketing and promotion of Senaparib in China. As the Marketing Authorization Holder (MAH) of the licensed product, IMPACT Therapeutics will be responsible for its registration, clinical development, manufacturing, supply, and distribution. IMPACT Therapeutics will receive an upfront payment of RMB 100 million and milestone payments for registration and commercialization of up to RMB 190 million. Additionally, IMPACT Therapeutics will pay Huadong Medicine marketing service fees based on future net sales.

Senaparib (IMP4297), a novel and highly potent PARP1/2 inhibitor independently developed by IMPACT Therapeutics, features a unique molecular structure that ensures excellent target selectivity and a broad safety window. The Phase III registrational study of senaparib as first-line maintenance therapy for the entire population with advanced ovarian cancer (FLAMES) has met its primary endpoint. In August 2022, the fixed-dose combination capsule of senaparib and temozolomide (TMZ) for the treatment of adult patients with small cell lung cancer (SCLC) was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA). In August 2023, the National Medical Products Administration accepted the New Drug Application (NDA) for senaparib in China.

IMPACT Therapeutics is dedicated to the research and development of world-class, innovative targeted anti-cancer drugs with independent intellectual property rights, focusing on the mechanism of synthetic lethality. Building on its independently developed products targeting the DNA damage response (DDR) pathway, the company has established one of the most comprehensive DDR product portfolios among global biopharmaceutical companies and is progressively expanding into additional novel synthetic lethality targets. The company’s pipeline includes the PARP inhibitor senaparib (IMP4297), the WEE1 inhibitor IMP7068, the ATR inhibitor IMP9064, the PARP1-selective inhibitor IMP1734 (co-developed with Eikon Therapeutics in the United States), and inhibitors targeting several other DDR pathways.

Huadong Medicine Co., Ltd. (SZ.000963), founded in 1993 and headquartered in Hangzhou, Zhejiang, adheres to the corporate philosophy of “science-based, patient-centric.” Over the past 30 years, the company has expanded its business across the entire pharmaceutical industry chain, encompassing four core segments: pharmaceutical manufacturing, pharmaceutical commerce, medical aesthetics, and industrial microbiology. It has grown into a large, comprehensive listed pharmaceutical enterprise integrating R&D, production, and distribution. The company’s innovative drug portfolio and R&D pipeline focus on oncology, immunology, and endocrinology. With more than 14,000 employees, Huadong Medicine boasts extensive commercial coverage and strong marketing capabilities.